Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Elizabeth L. Hougen sold 4,000 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $57.00, for a total transaction of $228,000.00. Following the sale, the senior vice president now directly owns 14,392 shares of the company’s stock, valued at $820,344. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at $54.60 on Friday. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. The stock has a market cap of $6,730.22, a P/E ratio of 359.53 and a beta of 2.85. Ionis Pharmaceuticals, Inc. has a 52-week low of $37.26 and a 52-week high of $65.51.

Large investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new position in Ionis Pharmaceuticals in the third quarter worth approximately $100,000. Parallel Advisors LLC increased its holdings in Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after buying an additional 800 shares during the last quarter. Hanseatic Management Services Inc. increased its holdings in Ionis Pharmaceuticals by 1.2% in the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after buying an additional 41 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after buying an additional 311 shares during the last quarter. Finally, WFG Advisors LP increased its holdings in Ionis Pharmaceuticals by 77.2% in the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after buying an additional 1,655 shares during the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.

A number of analysts have commented on IONS shares. Stifel Nicolaus reaffirmed a “hold” rating and set a $50.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price objective for the company in a research note on Friday, October 27th. Morgan Stanley upped their price objective on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. BMO Capital Markets upped their price objective on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Finally, Barclays started coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $50.31.

COPYRIGHT VIOLATION WARNING: “Elizabeth L. Hougen Sells 4,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/09/elizabeth-l-hougen-sells-4000-shares-of-ionis-pharmaceuticals-inc-ions-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.